Delving into the Latest Updates on Anti-rabies monoclonal antibody(MassBiologics) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-rabies monoclonal antibody, RMab, Rabies human monoclonal antibody

+ [3]

Target

RABV-G

Mechanism

RABV-G inhibitors(RABV-G inhibitors)

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication

Rabies

Inactive Indication

Immune System DiseasesInflammationNeoplasms

Originator Organization

MassBiologics

Active Organization

Serum Institute of India Pvt Ltd.MassBiologics

Inactive Organization

PharmaPraxis

Drug Highest PhaseApproved

First Approval Date

IN (01 Jan 2016),

Rabies

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 11821L

Sequence Code 11816H

Given the growing popularity of Rituximab (Rmab) treatment as a potential substitute for cyclophosphamide, we conducted this review to determine aspects related to Rmab therapy in central nervous system vasculitis (CNSV) patients, aiming to establish both the beneficial and detrimental consequences of Rmab while providing clinical guidance for managing patients' conditions. This systematic review was prepared following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The PubMed, Web of Science, and Scopus databases were utilized to investigate Rmab treatment in CNSV from January 2015 to May 2024. The research question was structured using the Population, Intervention, Comparison, Outcome, and Study Design (PICOS) criteria. Case series with only three or more unique cases, prospective or retrospective non-randomized studies, and randomized controlled trials (RCTs) were addressed. The initial evaluations were performed in PubMed, Scopus, and Web of Science. After removing duplicate entries, 177 publications were obtained, and 41 were chosen for full-text assessment. The review then incorporated information gathered from 27 studies, including 4 case series, 15 non-randomized cohorts, and 8 RCTs. Rmab is generally regarded as effective for CNSV therapy. Given its success, induction Rmab therapy is now frequently employed as maintenance therapy for CNSV patients. Rmab is a viable option for the induction of remission and maintenance treatment, with a successful reduction in relapse rates.

01 Sep 2024·Joint Bone Spine

Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-report

Article

Author: Krikelis, Michail ; Makris, Konstantinos ; Trovas, Georgios ; Tournis, Symeon ; Chronopoulos, Efstathios ; Gazi, Susana

INTRODUCTIONDenosumab (Dmab) is widely used for the treatment of post-menopausal osteoporosis. Its discontinuation is sometimes accompanied by multiple vertebral fractures. Romosozumab (Rmab) has not been tested for its ability to prevent the rebound phenomenon.CASE PRESENTATIONWe present the case of a 68-year-old female patient with post-menopausal osteoporosis under treatment with Rmab who presented with multiple vertebral fractures after denosumab discontinuation. The addition of Rmab did not prevent new-onset rebound-associated vertebral fractures. The patient discontinued Rmab and Dmab was re-initiated. After six months, no new vertebral fractures occurred, bone mineral density increased and bone turnover markers remained suppressed.DISCUSSIONOur clinical case illustrates the ineffectiveness of Rmab to prevent the multiple vertebral fracture cascade attributable to discontinuation of Dmab. We believe that treatment with Rmab might not be enough to prevent this phenomenon. Treatment with Dmab or possibly combination treatment with Dmab and Rmab could be another treatment option.

11 Mar 2024·Human Vaccines & ImmunotherapeuticsQ3 · MEDICINE

Defining the volume of rabies immunoglobulins/ rabies monoclonal antibodies requirement for wound infiltration of category III animal exposures – an exploratory study

Q3 · MEDICINE

Article

Author: Prashanth, Ramya M. ; Surendran, Jithin ; Sudarshan, Mysore K. ; Narayana, D. H. Ashwath ; Haradanhalli, Ravish S. ; Kumari, Nitu

WHO recommends infiltration of rabies immunoglobulins/rabies monoclonal antibodies as anatomically possible, into or close to all category III animal bite wound(s)/exposures for post exposure prophylaxis. The volume required for wound infiltration depending upon the site/size/severity of wound is yet to be defined for guiding the treating physicians. This study aimed to determine the volume of rabies immunoglobulin/rabies monoclonal antibody required for wound infiltration depending upon the site, size, and severity. A prospective cohort study was conducted including category III animal exposures at the anti-rabies clinic, KIMS hospital and Research Center, Bangalore, India. The volume of rabies immunoglobulins/rabies monoclonal antibodies required for wound infiltration, depending on site, severity, and size was determined. All the subjects were followed for 6 months to demonstrate the safety and clinical efficacy of post exposure prophylaxis. The present study included 717 subjects having 1428 bite wounds. There was a significant difference in the median volume required for wound infiltration based on site, size, and severity of bite wounds. However, on pairwise comparison; the median volume among all the pairs for only wound size was found to be statistically significant. Supportively, a strong positive correlation was seen with the size of wound and volume infiltrated. The volume of rabies immunoglobulin/rabies monoclonal antibodies required for wound infiltration shall be determined according to size of wounds, i.e. 1 ml for <1 cm wound, 3 ml for 1-5 cm wound, and 5 ml for >5 cm wound.

100 Deals associated with Anti-rabies monoclonal antibody(MassBiologics)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J06BB05	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rabies	IN	-	01 Jan 2016

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immune System Diseases	Phase 3	BR	PharmaPraxis	23 Apr 2012
Inflammation	Phase 3	BR	PharmaPraxis	23 Apr 2012
Neoplasms	Phase 3	BR	PharmaPraxis	23 Apr 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTRI/2012/05/002709 (Pubmed \| Clin Infect Dis)	Phase 2/3	-	200	SII RMAb	gcgdvkzqjq(tvczihlpeo) = fobsxmmiik fqjsnzjskc (xvqfmwsekj, 18.94 - 32.74)	Positive	18 Jan 2018
				HRIG	gcgdvkzqjq(tvczihlpeo) = gblgitsdqj fqjsnzjskc (xvqfmwsekj, 4.11 - 8.41)
EULAR2003	Phase 2	Rheumatoid Arthritis CD19 \| CD3 \| IgG ... View more	161	MTX	yrnsrspenx(ivorwynnkj) = dljbmsysli znmybykcao (cvapfoeswx ) View more	Positive	18 Jun 2003
				Rmab	yrnsrspenx(ivorwynnkj) = ujxgyetxem znmybykcao (cvapfoeswx ) View more